JP4898049B2 - デスレセプター誘導アポトーシスによる免疫調節 - Google Patents

デスレセプター誘導アポトーシスによる免疫調節 Download PDF

Info

Publication number
JP4898049B2
JP4898049B2 JP2001552725A JP2001552725A JP4898049B2 JP 4898049 B2 JP4898049 B2 JP 4898049B2 JP 2001552725 A JP2001552725 A JP 2001552725A JP 2001552725 A JP2001552725 A JP 2001552725A JP 4898049 B2 JP4898049 B2 JP 4898049B2
Authority
JP
Japan
Prior art keywords
cells
chimeric protein
cell
fasl
apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001552725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003520214A5 (enExample
JP2003520214A (ja
Inventor
シャーワン，ハバル
Original Assignee
ユニバーシティ オブ ルイビル リサーチ ファウンデーション，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ ルイビル リサーチ ファウンデーション，インコーポレイティド filed Critical ユニバーシティ オブ ルイビル リサーチ ファウンデーション，インコーポレイティド
Publication of JP2003520214A publication Critical patent/JP2003520214A/ja
Publication of JP2003520214A5 publication Critical patent/JP2003520214A5/ja
Application granted granted Critical
Publication of JP4898049B2 publication Critical patent/JP4898049B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
JP2001552725A 2000-01-24 2001-01-24 デスレセプター誘導アポトーシスによる免疫調節 Expired - Fee Related JP4898049B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17803800P 2000-01-24 2000-01-24
US60/178,038 2000-01-24
US21558000P 2000-06-30 2000-06-30
US60/215,580 2000-06-30
PCT/US2001/002256 WO2001052664A1 (en) 2000-01-24 2001-01-24 Immune modulation with death receptor-induced apoptosis

Publications (3)

Publication Number Publication Date
JP2003520214A JP2003520214A (ja) 2003-07-02
JP2003520214A5 JP2003520214A5 (enExample) 2008-03-27
JP4898049B2 true JP4898049B2 (ja) 2012-03-14

Family

ID=26873890

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001552725A Expired - Fee Related JP4898049B2 (ja) 2000-01-24 2001-01-24 デスレセプター誘導アポトーシスによる免疫調節

Country Status (7)

Country Link
EP (1) EP1250055B1 (enExample)
JP (1) JP4898049B2 (enExample)
AT (1) ATE481475T1 (enExample)
AU (1) AU784614B2 (enExample)
CA (1) CA2396979C (enExample)
DE (1) DE60143074D1 (enExample)
WO (1) WO2001052664A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927602B2 (en) 2002-07-23 2011-04-19 University Of Louisville Research Foundation, Inc. Fas ligand-avidin/streptavidin fusion proteins
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
WO2002002751A2 (en) * 2000-06-30 2002-01-10 University Of Louisville Research Foundation, Inc. Alteration of cell membrane
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
AU2020334237B2 (en) * 2019-08-19 2025-11-13 Universität Basel Cell therapy methods
CN115717124B (zh) * 2022-11-23 2025-05-16 香港城市大学深圳福田研究院 用于分离外泌体的纳米材料及其制备方法、应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007828A1 (en) * 1995-08-30 1997-03-06 The Regents Of The University Of California Therapy for cellular accumulation in chronic inflammatory diseases
WO1997033617A1 (en) * 1996-03-13 1997-09-18 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
WO1998020896A1 (en) * 1996-11-15 1998-05-22 Health Research Inc. A method for inducing apoptosis of primary central nervous system b cell lymphomas
WO1999017801A2 (en) * 1997-10-03 1999-04-15 Cancer Research Campaign Technology Limited Materials and methods relating to the stimulation of cells
JP2000500336A (ja) * 1995-11-16 2000-01-18 ノバルティス アクチエンゲゼルシャフト Ｆａｓリガンド融合タンパク質

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101004174B1 (ko) * 1995-06-29 2010-12-24 임뮤넥스 코포레이션 세포소멸을 유도하는 시토킨

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007828A1 (en) * 1995-08-30 1997-03-06 The Regents Of The University Of California Therapy for cellular accumulation in chronic inflammatory diseases
JP2000500336A (ja) * 1995-11-16 2000-01-18 ノバルティス アクチエンゲゼルシャフト Ｆａｓリガンド融合タンパク質
WO1997033617A1 (en) * 1996-03-13 1997-09-18 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
WO1998020896A1 (en) * 1996-11-15 1998-05-22 Health Research Inc. A method for inducing apoptosis of primary central nervous system b cell lymphomas
WO1999017801A2 (en) * 1997-10-03 1999-04-15 Cancer Research Campaign Technology Limited Materials and methods relating to the stimulation of cells

Also Published As

Publication number Publication date
WO2001052664A1 (en) 2001-07-26
EP1250055A4 (en) 2003-04-23
ATE481475T1 (de) 2010-10-15
CA2396979A1 (en) 2001-07-26
DE60143074D1 (de) 2010-10-28
CA2396979C (en) 2015-07-14
EP1250055B1 (en) 2010-09-15
JP2003520214A (ja) 2003-07-02
EP1250055A1 (en) 2002-10-23
AU784614B2 (en) 2006-05-11
AU3293301A (en) 2001-07-31

Similar Documents

Publication Publication Date Title
US8551494B2 (en) Methods of immune modulation with death receptor-induced apoptosis
ES2353637T3 (es) Moléculas denominadas ldcam.
JP4451059B2 (ja) 分泌及び膜貫通ポリペプチドとそれをコードする核酸
TWI222453B (en) Ligand for herpes simplex virus entry mediator and methods of use
JPH10512440A (ja) サイトカイン”ｌｅｒｋ−７”
JPH06509462A (ja) レセプターキメラ体による細胞性免疫の再設定
JP2006137774A (ja) 新規なポリペプチド及びそれをコードする核酸
PL207501B1 (pl) Zastosowanie polipeptydu BCMA oraz przeciwciała skierowanego przeciwko BCMA
JP2001523099A (ja) 白血球免疫グロブリン様受容体（ｌｉｒ）と命名される免疫調節剤ファミリー
AU2009246044B2 (en) Methods of detecting cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells
DE60035693T2 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
JP2000504586A (ja) ヘテロ二量体を形成するハイブリッドタンパク質
JP2004524806A (ja) 新しい機能のための細胞膜の変更
JP4898049B2 (ja) デスレセプター誘導アポトーシスによる免疫調節
EA006874B1 (ru) Полипептид, обладающий активностью rap [белка, ассоциированного с rip (взаимодействующим с рецептором белком)], кодирующая его последовательность днк и способы их получения и использования
JP4242371B2 (ja) 免疫関連疾患を治療するための組成物及び方法
JP2003517311A (ja) カスパーゼにより誘導されるアポトーシスのための組成物および方法
AU2004234532A1 (en) SPEX compositions and methods of use
JP2001501455A (ja) 分泌蛋白をコードするポリヌクレオチド
JP5967448B2 (ja) ２型ｔｎｆ受容体の発現を誘導する合成ペプチド及びその利用
EP1027436A1 (en) Viral encoded semaphorin protein receptor dna and polypeptides
ES2201547T3 (es) Icam-4 y usos diagnosticos de las mismas.
Ryffel et al. Correction of the TNF‐LTα‐Deficient Phenotype by Bone Marrow Transplantation
Mokada-Gopal STAT6 regulated B cell responses
JP2003047470A (ja) 新規な抗体及びその用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101021

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110530

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111129

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111226

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150106

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees